Routes of
administration Inhalation Legal status Experimental CAS Number 915133-65-2 Molar mass 403.898 g/mol | ATC code None Biological half-life 24.3 hours PubChem CID 11962616 | |
 | ||
How to pronounce abediterol
Abediterol (INN) (codenamed AZD-0548, LAS 100977) is a novel, once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials.
It acts as a β2 adrenergic agonist and is classified as an ultra-long-acting β2 agonist (ultra-LABA).
Its coformulation with mometasone furoate is also in Phase II clinical trials.
References
Abediterol Wikipedia(Text) CC BY-SA